MicrOwave and laSer ablaTion Study (MOST Study)

Varicose Veins of Lower Limb Clinical Trial

— MOST  

Official title:

A Prospective, Multicenter, Randomized, Controlled Clinical Trial to Validate the Safety and Efficacy of Microwave Versus Laser Ablation of the Great Saphenous Vein in Patients With Varicose Veins

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04726124
• Other study ID #: SD-LC-001
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 26, 2021
• Est. completion date: September 28, 2022

Study information

• Verified date: October 2021
• Source: Beijing Tsinghua Chang Gung Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To validate the safety and efficacy of microwave versus laser ablation of the great saphenous vein in patients with varicose veins of lower extremities

Description:

A prospective, multicenter, randomized, controlled clinical trial to validate the safety and efficacy of microwave versus laser ablation of the great saphenous vein in patients with varicose veins of lower extremities

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 180
• Est. completion date: September 28, 2022
• Est. primary completion date: September 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age 18 years or older, not older than 80 years, male or female

2. Patients clinically diagnosed as primary great saphenous vein insufficiency with reflux lasting > 0.5 seconds on duplex ultrasound

3. Patients with CEAP grade C2-C6

4. Patients who voluntarily participate in this trial, understand all the risks and benefits described in the informed consent document, and sign the written informed consent form

Exclusion Criteria:

1. Patients with diameter of target lesion vein < 2 mm or > 15 mm

2. Patients with previous surgical treatment on the target lesion or patients with acute thrombosis

3. Patients with deep vein thrombosis and superficial vein thrombosis

4. Patients with acute systemic infectious diseases

5. Patients with severe liver and kidney dysfunction (ALT > 3 times the upper limit of normal value; creatinine > 225 umol /L)

6. Patients with known uncorrectable bleeding or severe coagulopathy

7. Patients with anesthesia contraindications

8. Patients with poorly controlled hypertension (systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg) and diabetes mellitus (fasting glucose = 10.0 mmol / L)

9. Patients with non-primary varicose veins caused by post-deep vein thrombosis syndrome, KT syndrome (Klippel-Trenaunay syndrome), arteriovenous fistula, etc.

10. Patients with other diseases that may cause difficulty in conducting the trial or evaluation, such as mental illness, AIDS, malignant tumors, liver disease, cardiac insufficiency, etc. or patients whose life expectancy is less than 1 year

11. Pregnant, lactating women, or those planning on becoming pregnant during the trial

12. Patients who have participated in clinical trials of other drugs or medical devices in the past 3 months

13. Patients considered unsuitable for inclusion by investigators for other reasons

Related Conditions & MeSH terms

• Varicose Veins
• Varicose Veins of Lower Limb

Intervention

Device:
• Microwave Ablation Therapeutic Apparatus
The selected and qualified subjects with primary lower extremity varicose veins were randomly treated with microwave ablation equipment or laser treatment equipment. Subjects in the two groups were returned to the hospital for follow-up at 7 days, 3 months, 6 months, 12 months after surgery, respectively, for ultrasound examination and questionnaire evaluation, medication status and adverse events were recorded, and target lesion closure rate and subject satisfaction were evaluated.

Locations

Country	Name	City	State
China	Beijing Tsinghua Chang Gung Hosipital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Tsinghua Chang Gung Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the complete closure rate of great saphenous vein at 6 months after surgery	Complete closure: Doppler ultrasonography showed that the target vein segment of the entire treatment is closed, with no discontinuous unclosed segment more than 5 cm.; Calculation method: Complete closure rate = number of subjects with complete closure of target vein in the group/total number of subjects in the same group × 100%.; The B-ultrasound check is performed on subjects 6 months after the surgery for whether the target vein is completely closed, the result is recorded. After the trial is completed, the number of subjects whose target vein is completely closed is counted, and the complete closure rate of great saphenous vein is calculated.	6 months after surgery
Secondary	the complete closure rate of great saphenous vein at 12 months after surgery	Complete closure: Doppler ultrasonography showed that the target vein segment of the entire treatment is closed, with no discontinuous unclosed segment more than 5 cm.; Calculation method: Complete closure rate = number of subjects with complete closure of target vein in the group/total number of subjects in the same group × 100%.; The B-ultrasound check is performed on subjects 12 months after the surgery for whether the target vein is completely closed, the result is recorded. After the trial is completed, the number of subjects whose target vein is completely closed is counted, and the complete closure rate of great saphenous vein is calculated.	12 months after surgery
Secondary	surgical success rate	Successful surgery: Doppler ultrasound examination shows that the target lesion segment is closed immediately after operation.; Calculation method: Surgical success rate = number of subjects successfully operated in this group/total number of subjects in this group × 100%	immediately after surgery
Secondary	device performance evaluation	During or after the surgery, the manipulation performance of the device is evaluated by the investigator,which is include flexibility, passability, ease of use, accuracy, stability etc.. Only the device in the test group is evaluated.	during or after surgery
Secondary	changes of venous clinical severity score (VCSS) before and after treatment	VCSS is performed in the screening period, 30 days after surgery, 3 months and 6 months after surgery. The VCSS includes 10 items, namely, pain, varicose veins, edema, skin pigmentation, inflammation, skin induration, number of active ulcers, ulcer size, duration of ulcers and application of compression therapy. Each item is scored from 0 to 3 according to the severity of the disease, with a total score of 30. The higher the score, the more serious the condition.	screening period, 30days, 3 months, 6months, 12 months after surgery
Secondary	changes of Aberdeen Varicose Vein Questionnaire (AVVQ) score before and after treatment	Aberdeen Varicose Vein Questionnaire (AVVQ) score before and after treatment AVVQ score is performed in the screening period, 30 days after surgery, 3 months and 6 months after surgery. AVVQ includes the scope of varicose veins, the degree of pain, edema, itching, pigmentation, rash and ulcers, the use of painkillers and elastic stockings, the psychological worries, and the influence of varicose veins on daily clothing, work, life and sports. Each item is scored from 0 to 3 according to the severity of the disease. The lower the score, the better the quality of life.	screening period, 30 days, 3 months, 6 months, 12 months after surgery
Secondary	time of surgery	After the surgery, the operation time is recorded. The operation time is defined as the time from the entry of the investigational device into the vein to the withdrawal of the vein after the treatment.	immediately after surgery